Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Sleep and Anesthesia - Common mechanisms of action.

Vacas S, Kurien P, Maze M.

Sleep Med Clin. 2013 Mar;8(1):1-9. doi: 10.1016/j.jsmc.2012.11.009. No abstract available.

2.

Methoxetamine affects brain processing involved in emotional response in rats.

Zanda MT, Fadda P, Antinori S, Di Chio M, Fratta W, Chiamulera C, Fattore L.

Br J Pharmacol. 2017 Oct;174(19):3333-3345. doi: 10.1111/bph.13952. Epub 2017 Aug 19.

PMID:
28718892
3.

Reduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode Psychosis.

Nagai T, Kirihara K, Tada M, Koshiyama D, Koike S, Suga M, Araki T, Hashimoto K, Kasai K.

Sci Rep. 2017 May 23;7(1):2258. doi: 10.1038/s41598-017-02267-1.

4.

Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation.

Rame M, Caudal D, Schenker E, Svenningsson P, Spedding M, Jay TM, Godsil BP.

PLoS One. 2017 May 4;12(5):e0177036. doi: 10.1371/journal.pone.0177036. eCollection 2017.

5.

Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.

Maksymetz J, Moran SP, Conn PJ.

Mol Brain. 2017 Apr 26;10(1):15. doi: 10.1186/s13041-017-0293-z. Review.

6.

Zinc in the Monoaminergic Theory of Depression: Its Relationship to Neural Plasticity.

Doboszewska U, Wlaź P, Nowak G, Radziwoń-Zaleska M, Cui R, Młyniec K.

Neural Plast. 2017;2017:3682752. doi: 10.1155/2017/3682752. Epub 2017 Feb 19. Review.

7.

The Role of Dopamine D1 and D3 Receptors in N-Methyl-D-Aspartate (NMDA)/GlycineB Site-Regulated Complex Cognitive Behaviors following Repeated Morphine Administration.

Wang Y, Yin F, Guo H, Zhang J, Yan P, Lai J.

Int J Neuropsychopharmacol. 2017 Feb 11. doi: 10.1093/ijnp/pyx010. [Epub ahead of print]

8.

The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia.

Griebel G, Pichat P, Boulay D, Naimoli V, Potestio L, Featherstone R, Sahni S, Defex H, Desvignes C, Slowinski F, Vigé X, Bergis OE, Sher R, Kosley R, Kongsamut S, Black MD, Varty GB.

Sci Rep. 2016 Oct 13;6:35320. doi: 10.1038/srep35320.

9.

Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.

Rotroff DM, Corum DG, Motsinger-Reif A, Fiehn O, Bottrel N, Drevets WC, Singh J, Salvadore G, Kaddurah-Daouk R.

Transl Psychiatry. 2016 Sep 20;6(9):e894. doi: 10.1038/tp.2016.145.

10.

Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters.

Can A, Zanos P, Moaddel R, Kang HJ, Dossou KS, Wainer IW, Cheer JF, Frost DO, Huang XP, Gould TD.

J Pharmacol Exp Ther. 2016 Oct;359(1):159-70. doi: 10.1124/jpet.116.235838. Epub 2016 Jul 28.

11.

Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs.

Muguruza C, Meana JJ, Callado LF.

Front Pharmacol. 2016 May 20;7:130. doi: 10.3389/fphar.2016.00130. eCollection 2016. Review.

12.

Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine.

Hudson MR, Rind G, O'Brien TJ, Jones NC.

Transl Psychiatry. 2016 Apr 19;6:e784. doi: 10.1038/tp.2016.51.

13.

Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine.

Wohleb ES, Gerhard D, Thomas A, Duman RS.

Curr Neuropharmacol. 2017;15(1):11-20. Review.

14.

Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.

Gerhard DM, Wohleb ES, Duman RS.

Drug Discov Today. 2016 Mar;21(3):454-64. doi: 10.1016/j.drudis.2016.01.016. Epub 2016 Feb 6. Review.

15.

Prefrontal glutamate correlates of methamphetamine sensitization and preference.

Lominac KD, Quadir SG, Barrett HM, McKenna CL, Schwartz LM, Ruiz PN, Wroten MG, Campbell RR, Miller BW, Holloway JJ, Travis KO, Rajasekar G, Maliniak D, Thompson AB, Urman LE, Kippin TE, Phillips TJ, Szumlinski KK.

Eur J Neurosci. 2016 Mar;43(5):689-702. doi: 10.1111/ejn.13159. Epub 2016 Feb 22.

16.

Inducible Nitric Oxide Inhibitors Block NMDA Antagonist-Stimulated Motoric Behaviors and Medial Prefrontal Cortical Glutamate Efflux.

Bergstrom HC, Darvesh AS, Berger SP.

Front Pharmacol. 2015 Dec 15;6:292. doi: 10.3389/fphar.2015.00292. eCollection 2015.

17.

mGlu2 Receptor Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards Their Primary Efficacy on Sleep Measures in Rats.

Ahnaou A, Lavreysen H, Tresadern G, Cid JM, Drinkenburg WH.

PLoS One. 2015 Dec 11;10(12):e0144017. doi: 10.1371/journal.pone.0144017. eCollection 2015.

18.

Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy.

de la Fuente-Sandoval C, Reyes-Madrigal F, Mao X, León-Ortiz P, Rodríguez-Mayoral O, Solís-Vivanco R, Favila R, Graff-Guerrero A, Shungu DC.

Int J Neuropsychopharmacol. 2015 Sep 12;19(3):pyv105. doi: 10.1093/ijnp/pyv105.

19.

Ketamine and phencyclidine: the good, the bad and the unexpected.

Lodge D, Mercier MS.

Br J Pharmacol. 2015 Sep;172(17):4254-76. doi: 10.1111/bph.13222. Epub 2015 Jul 28. Review.

20.

Ketamine Alters Outcome-Related Local Field Potentials in Monkey Prefrontal Cortex.

Skoblenick KJ, Womelsdorf T, Everling S.

Cereb Cortex. 2016 Jun;26(6):2743-2752. doi: 10.1093/cercor/bhv128. Epub 2015 Jun 3.

Supplemental Content

Support Center